OncoMatch/Clinical Trials/NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Is NCT04655092 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies P1101 (Ropeginterferon alfa-2b) for polycythemia vera (pv).
Treatment: P1101 (Ropeginterferon alfa-2b) — This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Prior therapy
Must have received:
Patients who have completed the 52-week treatment duration in Study A19-201
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify